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Abstract
Type 1 diabetes with periodontitis shows elevated TNF-α expression. Tumor necrosis factor
(TNF)-α stimulates the expression of receptor activator of nuclear factor-κB ligand (RANKL)
and sclerostin. The objective of this study was to determine the effect of TNF-α expression
of osteocytic RANKL and sclerostin in type 1 diabetes rats with periodontitis using infliximab
(IFX), a TNF-α antagonist. Rats were divided into two timepoint groups: day 3 and day 20.
Each timepoint group was then divided into four subgroups: 1) control (C, n = 6 for each time
point); 2) periodontitis (P, n = 6 for each time point); 3) diabetes with periodontitis (DP, n = 8
for each time point); and 4) diabetes with periodontitis treated with IFX (DP+IFX, n = 8 for
each time point). To induce type 1 diabetes, rats were injected with streptozotocin (50 mg/
kg dissolved in 0.1 M citrate buffer). Periodontitis was then induced by ligature of the man-
dibular first molars at day 7 after STZ injection (day 0). IFX was administered once for the 3
day group (on day 0) and twice for the 20 day group (on days 7 and 14). The DP group
showed greater alveolar bone loss than the P group on day 20 (P = 0.020). On day 3, higher
osteoclast formation and RANKL-positive osteocytes in P group (P = 0.000 and P = 0.011,
respectively) and DP group (P = 0.006 and P = 0.017, respectively) than those in C group
were observed. However, there was no significant difference in osteoclast formation or
RANKL-positive osteocytes between P and DP groups. The DP+IFX group exhibited lower
alveolar bone loss (P = 0.041), osteoclast formation (P = 0.019), and RANKL-positive osteo-
cytes (P = 0.009) than that of the DP group. On day 20, DP group showed a lower osteoid
area (P = 0.001) and more sclerostin-positive osteocytes (P = 0.000) than P group. On days
3 and 20, the DP+IFX group showed more osteoid area (P = 0.048 and 0.040, respectively)
but lower sclerostin-positive osteocytes (both P = 0.000) than DP group. Taken together,
these results suggest that TNF-α antagonist can diminish osteocytic RANKL/sclerostin
expression and osteoclast formation, eventually recovering osteoid formation. Therefore,
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TNF-αmight mediate alveolar bone loss via inducing expression of osteocytic RANKL and
sclerostin in type 1 diabetes rats with periodontitis.
Introduction
Bone loss is determined by the degree of bone resorption and bone formation. Many factors
can affect bone resorption and formation, including hormone levels, aging, and innervation
[1–3]. Among various factors, receptor activator of nuclear factor-κB (RANKL) and sclerostin
are known to affect bone resorption and formation, respectively. RANKL induces osteoclast
formation via binding to RANK on osteoclast precursors [3]. RANKL is expressed in various
cells, including osteoblasts, periodontal ligament cells, lymphocytes, and osteocytes [4–8].
Sclerostin regulates bone formation by interrupting Wnt signaling [9]. It binds to low-density
lipoprotein receptor-related proteins 5 and 6 on the cell membrane of osteoblasts and inhibits
canonical Wnt/β-catenin signaling, reducing osteoblastic bone formation. Sclerostin is
expressed in osteocytes. In type 1 diabetes, bone resorption and bone formation are imbal-
anced and bone microstructure is altered, leading to bone fragility. Among complicated mech-
anisms of bone fragility, insulin deficiency with inflammation and glucose toxicity are
contributing factors [10–12].
Periodontal disease is an inflammatory disease of periodontal tissues. It is characterized
by alveolar bone loss. Patients with chronic periodontitis show higher RANKL levels in peri-
odontal tissues than healthy individuals [13]. RANKL inhibition via osteoprotegerin, a
RANKL inhibitor, blocks alveolar bone loss in rats with periodontitis [14]. Patients with
chronic periodontitis have higher sclerostin levels in gingival tissues and serum than non-
periodontitis individuals, suggesting a possible role of sclerostin in periodontal tissues [15].
In addition, sclerostin levels in gingival crevicular fluid are higher in patients with chronic
periodontitis than those in healthy individuals. However, these levels are decreased after
non-surgical periodontal treatment, suggesting that regulating sclerostin levels might be
used as a new therapeutic strategy to treat periodontal disease [16]. Furthermore, wild type
mice with periodontitis exhibit significant bone resorption compared to sclerostin knockout
mice with periodontitis [17]. We have previously found that osteocytic sclerostin expression
is inversely related to osteoid formation in rats with periodontitis [5]. Taken together, these
findings suggest that RANKL and sclerostin expression is involved in alveolar bone loss in
periodontitis.
Type 1 diabetes is a risk factor for periodontitis. Periodontitis is severe in type 1 diabetes
patients [18–21]. It has been reported that streptozotocin (STZ)-induced type 1 diabetes rats
with periodontitis exhibit more alveolar bone loss with less bone formation compared to rats
with periodontitis only [22]. Interestingly, the low bone formation in type 1 diabetes rats with
periodontitis is correlated with high osteocytic sclerostin expression, suggesting that bone for-
mation might be suppressed in type 1 diabetes with periodontitis via high osteocytic sclerostin
expression.
Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine expressed in periodontitis
[15, 23, 24]. Patients with periodontitis and type 1 diabetes have higher expression levels of
TNF-α than patients with periodontitis [25]. Similar finding has been reported in rats with
both periodontitis and type 1 diabetes [26]. TNF-α induces RANKL expression in osteoblasts,
periodontal ligament fibroblasts, and MLO-Y4, a murine osteocyte-like cell line [6, 27, 28]. It
also induces sclerostin expression in MLO-Y4 cells [6, 29]. However, whether TNF-α stimu-
lates osteocytic RANKL and sclerostin expressions in diabetes with periodontitis is currently
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unclear. Therefore, the objective of this study was to determine the effect of infliximab (IFX), a
TNF-α antagonist, on osteocytic RANKL and sclerostin expression in STZ-induced type 1 dia-
betes rats with periodontitis.
Materials and methods
Animals
Six-week male inbred F344 rats were purchased from Orient Bio Inc. (Seongnam, Korea) and
adapted for one week. These rats were housed in individual ventilated cages in groups of 3–4
animals per cage. They were provided access to fed standard rat chow (Orient-Bio Inc.) and
water ad libitum. The animals were maintained in a temperature-controlled room (22˚C) and
50 ± 10% humidity on a 12-hour light-dark cycle (light on 8:00–20:00). This study was carried
out in strict accordance with the recommendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The animal protocols were approved by
the institutional Animal Care and Use Committee of Yonsei University (approval number:
2014–0393). All efforts were made to minimize suffering.
Study design
Using GPower 3.1.9.2 software [30], it was predicted that at least 16 animals at each time point
(n = 4 per group, four groups) would be needed with effect size of 1.12, 80% power, and alpha
level at 0.05 in one-way analysis of variance (ANOVA). The experimental scheme is shown in
S1A Fig. Fifty-six rats were divided into two timepoint groups: 3 day group (n = 28) and 20 day
group (n = 28). Each timepoint group was then divided into the following 4 subgroups as follows:
1) untreated control (C, n = 6 at each time point); 2) periodontitis (P, n = 6 at each time point);
3) diabetes with periodontitis (DP, n = 8 at each time point), and 4) diabetes with periodontitis
treated with IFX (DP+IFX, n = 8 at each time point) groups. We allocated two additional rats for
DP and DP+IFX subgroups that underwent induction of diabetes. After fasting for 16 h, type 1
diabetes was induced by intravenous administration of STZ (Sigma-Aldrich, St Louis, MO, USA;
50 mg/kg dissolved in 0.1 M citrate buffer) under inhalation anaesthesia with 2% isoflurane in
oxygen (2l/min) for 2 min. Rats in non-diabetes groups were injected with citrate buffer alone.
At one week after administration of STZ or citrate buffer (day 0), rats were anesthetized intraper-
itoneally with zoletil 50 (30 mg/kg, Virbac, Carros, France) and rompun (10 mg/kg, Bayer Korea,
Ansan, Korea). Periodontitis was induced by bilateral ligature of the mandibular first molars
using dental floss (Procter & Gamble, Cincinnati, OH, USA). IFX (5 mg/kg, Janssen Biologics B.
V., Leiden, Netherlands) was administrated intraperitoneally once for the 3 day group (on day 0)
and twice for the 20 day group (on days 7 and 14). Each group was then sacrificed on either day
3 or day 20 after ligature using CO2 gas for reducing animal suffering.
Dental floss location and body weight were checked during the experiment periods (S1B
Fig). Right prior to sacrifice, blood glucose levels were measured using an Accu-Check active
system (Roche, Mannheim, Germany) after overnight fasting in accordance with the manufac-
turer’s instructions (S1C Fig).
Histological procedures
Upon sacrifice, mandibles were extracted. After fixation with 10% neutral buffered formalin
for two days, the mandibles were decalcified with 10% EDTA for two months. After tissue pro-
cessing procedures (dehydration, clearing, and infiltration), they were embedded in paraffin,
cut into serial 4 μm thick sagittal sections, and placed on silane-coated glass slides (Thermo
TNF-α and osteocytic RANKL and sclerostin in diabetes with periodontitis
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Fisher Scientific, Waltham, MA, USA). Sections were selected based on clear appearance of
dental pulp of mesial and distal roots of first molars.
Histomorphological analysis to evaluate alveolar bone loss and formation
To quantify alveolar bone loss, the distance from the cementoenamel junction (CEJ) to the alve-
olar bone crest (ABC) in the distal area of the first molar was measured under 10× objective in
hematoxylin and eosin (H&E) stained sections. To quantify new bone formation, the osteoid
area in the distal alveolar bone of the first molar was measured under 20× objective according
to previous studies [5]. The new osteoid was considered as unmineralized bone matrix (light
pink color) between osteoblasts which are cuboidal bone-lining cells and mineralized bone sur-
face stained as pink color in H&E sections. Images were taken using an Olympus microscope
system (CKX41, Tokyo, Japan) and analyzed using ImagePro software (Media Cybernetics, Sil-
ver Spring, MD, USA). Measurement of osteoid formation was carried out in a region of inter-
est (ROI) that extended 0.5 mm from the ABC in the distal alveolar bone of the first molar. The
individual who performed the analysis was blinded to experimental conditions. Measurements
of CEJ-ABC distance and osteoid area were conducted for all rats from each time point.
Immunohistochemical analysis
Following deparaffinization in xylene and rehydration using ethanol, slide sections were
immersed in 3% hydrogen peroxide for 20 min. Sections were incubated with trypsin (Thermo
Fisher Scientific, Waltham, MA, USA) for antigen retrieval. ImmPRESS kits (MP-7405; Vector
Laboratories, Burlingame, CA, USA) were used for immunohistochemistry staining according
to the manufacturer’s instructions. Sections were blocked with normal horse blocking reagent
(provided by ImmPRESS kits) for 20 min. To identify osteoclast formation, sections were
immunostained with goat polyclonal anti-cathepsin K antibody (1:75; sc-6507; Santa Cruz Bio-
technology Inc, Santa Cruz, CA, USA) at 4˚C overnight. To measure RANKL and sclerostin
expression in osteocytes, sections were immunostained with goat polyclonal anti-RANKL anti-
body (1:500; sc-7628; Santa Cruz Biotechnology Inc.) and goat polyclonal anti-sclerostin anti-
body (1:300; AF1589; R&D Systems, Minneapolis, MN, USA), respectively, at 4˚C overnight.
These section were incubated with secondary antibody (provided by ImmPRESS kits) followed
by incubation with peroxidase-labeled streptavidin (Abcam, Cambridge, UK) for 20 min.
Color was developed using substrate-chromogen (Dako, Carpinteria, CA, USA) and counter-
stained with methyl green (Trevigen, Gaithersburg, MD, USA). Primary antibodies were
omitted as negative controls. Sections used as negative control did not display any specific
immunoreactivity. Images were taken with an Olympus microscope system using 40× objec-
tive and analyzed with ImagePro software. Measurements of cathepsin K-positive multinu-
cleated cells and RANKL- and sclerostin-positive osteocytes were carried out in a ROI that
extended 0.5 mm from the ABC in the distal alveolar bone of the first molar. The number of
cathepsin K-positive multinucleated cells was counted along the alveolar bone surface in the
RIO and calculated per millimeter length of alveolar bone surface. The number of RANKL-
and sclerostin-positive osteocytes was divided by the number of total osteocytes to calculate a
percentage. The individual who performed the analysis was blinded to the experimental condi-
tions. Measurements of cathepsin K-, RANKL- and sclerostin-positive cells were conducted
for all rats from each time point.
Real-time polymerase chain reaction
Alveolar bones and gingival tissues of rat first molars were collected from half number of each
group at each time point (C, n = 3; P, n = 3; DP, n = 4; DP+IFX, n = 4 at each time point).
TNF-α and osteocytic RANKL and sclerostin in diabetes with periodontitis
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Total RNA was extracted from alveolar bones and gingival tissues using TRIzol reagent (Invi-
trogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. One μg of
total RNA was converted to complementary DNA (cDNA) using RT-PCR PreMix Kit (Bio-
neer, Seoul, Korea) according to the manufacturer’s instructions. Quantitative real-time PCR
was conducted using SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK)
and a MyiQ2 Two-Color Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA).
Specific real-time PCR primers for IL-1β, sclerostin, and GAPDH were listed in S1 Table. Rela-
tive gene expression quantification was normalized to GAPDH mRNA expression using 2-ΔΔ
Ct analysis method. We performed melting curve analyses to verify amplification specificity
and the absence of primer dimers.
Statistical analyses
All values are presented as mean ± standard error (SE). Data were evaluated by ANOVA fol-
lowed by Scheffe’s test. Statistical significance was determined using SPSS software (IBM, Chi-
cago, IL, USA). A P value of less than 0.05 was considered statistically significant.
Results
Alveolar bone loss
To observe the effect of IFX on alveolar bone loss in type 1 diabetes with periodontitis, we
measured the distance of CEJ (black arrow) to ABC (dotted line) in the distal area (Fig 1). On
day 3, distance from CEJ to ABC in the P or DP groups was longer than that in the C group
while that in DP+IFX group was shorter than that in the DP group. On day 20, the distance
from CEJ to ABC in the DP group was longer than that in the P group while that in the DP
+IFX group was shorter than that in the DP group.
Fig 1. Alveolar bone loss. Representative images of the distance from CEJ to ABC in each group. Black
arrows and dotted lines represent the CEJ and ABC, respectively (upper panels, H&E stain, scale
bar = 100 μm). Measurements of the distance from CEJ to ABC in each group (lower panel, C, n = 6; P, n = 6;
DP, n = 8; DP+IFX, n = 8 at each time point). Data are presented as mean ± SE. Data were evaluated by one-
way analysis of variance (ANOVA) followed by Scheffe’s test. A P value of less than 0.05 was considered
statistically significant. * P < 0.05 compared to C group; # P < 0.05; C: control group; P: periodontitis group;
DP: diabetes with periodontitis group; DP+IFX: diabetes with periodontitis treated with infliximab group.
https://doi.org/10.1371/journal.pone.0189702.g001
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Osteoclast formation
To evaluate the effect of IFX on osteoclast formation in type 1 diabetes with periodontitis, we
counted cathepsin K-positive multinucleated cells in the distal area (Fig 2A). On day 3, the
number of cathepsin K-positive cells in P or DP group was significantly higher than that in the
C group. However, the number was not significantly different between P and DP groups. The
number of cathepsin K-positive cells in DP+IFX group was lower than that in the DP or P
group. On day 20, the number of cathepsin K-positive cells in DP group was higher than that
in C, P, or DP+IFX group. There was no significant difference in the number of cathepsin K-
positive cells among C, P, and DP+IFX groups.
RANKL expression in osteocytes
To assess the effect of IFX on RANKL expression in type 1 diabetes with periodontitis, we
counted the number of RANKL-positive osteocytes in the distal area (Fig 2B). On day 3, the
number of RANKL-positive osteocytes in P or DP group was higher than that in the C group
while that number in DP+IFX group was markedly lower than that in DP or P group. Interest-
ingly, a high number of RANKL-positive osteocytes in the DP group was maintained on day
20 whereas DP+IFX and P groups exhibited lower numbers of RANKL-positive osteocytes
compared to DP group. It is known that TNF-α stimulates interleukin (IL)-1β proinflamma-
tory cytokine [24, 31, 32]. To determine whether IFX affected expression of IL-1β, IL-1β
mRNA expression levels in the gingival tissues of first molars were measured (Fig 2C). On day
3, IL-1β mRNA expression levels in P, DP, and DP+IFX groups were higher than those in the
C group. On day 20, we observed higher IL-1β mRNA expression in DP group than that in C
or P group. However, IL-1β mRNA expression in DP+IFX group was lower than that in DP
group.
Bone formation in alveolar bone
To investigate the effect of IFX on bone formation in type 1 diabetes with periodontitis, the
osteoid area was measured in the distal area (Fig 3). On day 3, the osteoid area in DP+IFX
group was larger than that in DP group. On day 20, the osteoid area in P group was greater
than that in C or DP group. Additionally, the osteoid area in DP+IFX group was much larger
than that in DP group.
Sclerostin expression in osteocytes
To determine the effect of IFX on osteocytic sclerostin expression in type 1 diabetes with peri-
odontitis, we counted the number of sclerostin-positive osteocytes (Fig 4A) and measured
sclerostin mRNA expression in alveolar bone of the distal area (Fig 4B). On day 3, the number
of sclerostin-positive osteocytes in P or DP group was significantly higher than that in C
group. However, the number of sclerostin-positive osteocytes in DP+IFX group was markedly
lower than that in DP or P group. On day 20, the high number of sclerostin-positive osteocytes
in DP group compared to that in C group was maintained whereas DP+IFX and P groups
showed fewer sclerostin-positive osteocytes than the DP group. On day 3, sclerostin mRNA
expression in DP+IFX group was lower than that in P or DP group. On day 20, we observed
no significant difference in sclerostin mRNA expression level among these groups.
Discussion
The precursor of TNF-α, a membrane-bound form, is expressed on the cell surface of activated
macrophages and lymphocytes [33]. The membrane form of TNF-α is cleaved and then
TNF-α and osteocytic RANKL and sclerostin in diabetes with periodontitis
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Fig 2. Cathepsin K-positive osteoclasts and RANKL-positive osteocytes in alveolar bone and IL-1β
mRNA expression levels in gingival tissues. (A) Representative images of the number of cathepsin K-
positive multinucleated cells in each group. Red arrowheads represent cathepsin K-positive multinucleated
cells (upper panels, scale bar = 100 μm). Quantification of the number of cathepsin K-positive multinucleated
cells in each group (lower panel, C, n = 6; P, n = 6; DP, n = 8; DP+IFX, n = 8 at each time point). (B)
TNF-α and osteocytic RANKL and sclerostin in diabetes with periodontitis
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released as soluble form of TNF-α. IFX is a mouse-human chimeric anti-human TNF-α anti-
body that inhibits the binding of soluble TNF-α to TNF receptors. In previous studies using a
TNF-α inhibitor, it has been demonstrated that TNF-α contributes to microvascular cell loss
in diabetic retinopathy [34]. TNF-α also accelerates cartilage loss during fracture healing in
type 1 diabetes rats or mice [35–38]. These findings indicate the TNF-α plays a crucial role in
various complications of type 1 diabetes. In previous studies, type 1 diabetes rats with peri-
odontitis have shown higher TNF-α expression and alveolar bone loss than rats with periodon-
titis [22, 26]. Our results showed that IFX, a TNF-α antagonist, decreased alveolar bone loss
and expression levels of osteocytic RANKL and sclerostin in STZ-induced diabetes rats with
periodontitis. This suggests that TNF-α is associated with alveolar bone loss in type 1 diabetes
with periodontitis.
Alveolar bone loss is caused by bone resorption and osteoclasts induce bone resorption. In
the present study, DP+IFX group showed lower number of cathepsin K-positive multinucle-
ated cells compared to DP group on days 3 and 20. Our data indicate that TNF-α is involved
in osteoclast formation in type 1 diabetes with periodontitis. The attenuation of osteoclast for-
mation by the TNF inhibitor has also been shown during the healing process of femoral frac-
ture in type 1 diabetes mice [35]. Pacios et al have recently reported that mice with periodontal
infection show more RANKL-positive osteocytes and osteoblasts than non-infected mice,
demonstrating that these cells contribute to osteoclast formation in periodontitis [6]. In addi-
tion, TNF-α has stimulatory effect on RANKL expression in osteocyte-like MLO-Y4 cells.
Percentage of RANKL-positive osteocytes in each group (C, n = 6; P, n = 6; DP, n = 8; DP+IFX, n = 8 at each
time point). (C) IL-1βmRNA expression levels in gingival tissues of each group (C, n = 3; P, n = 3; DP, n = 4;
DP+IFX, n = 4 at each time point). Data are presented as mean ± SE. Data were evaluated by one-way
analysis of variance (ANOVA) followed by Scheffe’s test. A P value of less than 0.05 was considered
statistically significant. * P < 0.05 compared to C group; # P < 0.05; n = number.
https://doi.org/10.1371/journal.pone.0189702.g002
Fig 3. Osteoid area in alveolar bone. Representative images of osteoid area in each group. Black dotted
lines indicate the osteoid area (upper panels, H&E stain, scale bar = 100 μm). Quantification of osteoid area in
each group (lower panel, C, n = 6; P, n = 6; DP, n = 8; DP+IFX, n = 8 at each time point). Data are presented
as mean ± SE. Data were evaluated by one-way analysis of variance (ANOVA) followed by Scheffe’s test. A P
value of less than 0.05 was considered statistically significant. * P < 0.05 compared to C group; # P < 0.05.
https://doi.org/10.1371/journal.pone.0189702.g003
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Interestingly, we found a lower number of RANKL-positive osteocytes in DP+IFX group than
that in DP group. This suggests that TNF-α is involved in osteocytic RANKL expression in
type 1 diabetes with periodontitis.
In addition to bone resorption, alveolar bone loss is also affected by bone formation. We
found that in the DP+IFX group had more bone formation on days 3 and 20 than the DP
group. Interestingly, the DP+IFX group showed lower numbers of sclerostin-positive osteo-
cytes on days 3 and 20 compared to DP group. It has been reported that TNF-α acts as an acti-
vator for sclerostin expression [29]. Additionally, serum sclerostin levels are higher in type 1
diabetes mice than those in normal mice [39]. One study has quantified sclerostin and TNF-α
expression levels in MLO-Y4 osteocyte-like cells under high glucose conditions [40]. MLO-Y4
osteocyte-like cells do not express appreciable levels of sclerostin under basal conditions [41].
However, they can be induced to express sclerostin under conditions of high-glucose or
Fig 4. Sclerostin expression in osteocytes of alveolar bone. (A) Representative images of sclerostin-
positive osteocytes in each group. White and red arrowheads indicate representative sclerostin-negative and
-positive osteocytes, respectively (upper panels, immunohistochemistry stain, scale bar = 100 μm).
Percentage of sclerostin-positive osteocytes in each group (lower panel, n = 6; P, n = 6; DP, n = 8; DP+IFX,
n = 8 at each time point). (B) Sclerostin mRNA expression in each group (C, n = 3; P, n = 3; DP, n = 4; DP
+IFX, n = 4 at each time point). Data are presented as mean ± SE. Data were evaluated by one-way analysis
of variance (ANOVA) followed by Scheffe’s test. A P value of less than 0.05 was considered statistically
significant. * P < 0.05 compared to C group; # P < 0.05.
https://doi.org/10.1371/journal.pone.0189702.g004
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exposure to reactive oxygen species [40]. H2O2-treated MLO-Y4 osteocyte-like cells also
showed high TNF-α and sclerostin expression compared to non-treated cells. Antioxidant
treatment and TNF-α knockdown attenuate high glucose-induced sclerostin expression, sug-
gesting that hyperglycemia induces high sclerostin expression via enhancing the production of
reactive oxygen species and TNF-α. Therefore, the attenuation of sclerostin-positive osteocytes
in IFX treated rats implicates the stimulatory effect of TNF-α on osteocytic sclerostin expres-
sion in type 1 diabetes with periodontitis.
This study has some limitations. First, alveolar bone loss and bone formation were not mea-
sured using micro-CT and/or biomechanical measurements. Such measurements are needed
for more clear confirmation of alveolar bone loss and bone formation. In previous studies, it
has been demonstrated that TNF-α may also mediate osteoclast formation via stimulating
RANKL expression in osteoblasts and periodontal ligament cells and extravasation of lympho-
cytes that can express RANKL [6, 27, 42–44]. Second, involvement of those cells in periodontal
tissue as source of RANKL could not be excluded in TNF-α-mediated osteoclast formation of
the type 1 diabetes with periodontitis. It is known that insulin/insulin like growth factor can
stimulate the differentiation of osteoblasts [10, 45]. Deficiency of insulin/insulin like growth
factor with anabolic activity on bone is associated with type 1 diabetes [10–12]. Besides TNF-
α-mediated mechanism in the current study, decreased osteoblastogenesis by insulin/insulin
like growth factor might also suppress bone formation in the type 1 diabetes with periodontitis.
Third, this needs to be considered in further studies.
In summary, we found that treatment with IFX, a TNF-α antagonist, could attenuate alveo-
lar bone loss, osteoclast formation, and RANKL-positive osteocytes in STZ-induced diabetes
rats with periodontitis. In addition, the IFX treatment induced high osteoid formation and low
sclerostin-positive osteocytes in STZ-induced diabetes rats with periodontitis. Our study sug-
gests that TNF-α might mediate osteocytic RANKL and the sclerostin expression in type 1 dia-
betes with periodontitis.
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